1Ohta M,Inoue H, Cotticelli MG, et al.The FHIT gene,spanning the chromosome 3p14.2 fragile site and renal carcinomaassociated t (3; 8) breakpoint , is abnormal in digestive tract cancers[J]. Cell, 1996,84:587-597.
2Barnes LD, Garrison PN, Siprashvili Z, et al. Fhit,a putative tumor suppressor in humans ,is a dinucleoside 5' 5"'-P1 ,P3-triphosphate hydrolase [ J ]. Biochemistry, 1996, 35 : 11529-11536.
3Said L, Accormro P, Tomielli S, et al. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control[J]. Proc Natl Acad Sci USA, 1999,96:8489-8492.
4Ji L, Fang B,Yen N,et al. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vectormediated fragile histidine triad (FHIT) gene overexpression[J]. Cancer Res, 1999,59:3333-3339.
5Siprashvili Z, Sozzi G, Barnes LD, et al. Replacement of Fhit in cancer cells suppresses tumorigenicity[ J]. Proc Nail Acad Sci USA, 1997,94:13771-13776.
6Lima CD, D Amico KL, Naday I, et al. MAD analysis of FHIT, a putative human tumor suppressor from the HIT protein family [J]. Structure , 1997,5:763-774.
7Chaudhuri AR,Khan IA,Prasad V,et al.The tumor suppressor protein Fhit:a novel interaction with tubutin[J]. J Biol Chem, 1999,274: 24378-24382.
8Hendricks DT, Taylor R,Reed M,et al. FHIT gene expression in human ovarian., endometrial, and cervical cancer cell lines[J] .Cancer Res, 1997,57:2112-2115.
9Greenspan DL, Connolly DC,Wu R,et al. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors[J]. Cancer Res, 1997,57:4692-4698.
10Krivak TC,McBmom JW, Seidmam J,et al. Abnormal fragile histidine triad (FHIT) expression in advanced cervical carcinoma: a poor prognostic factor [J]. Cancer Res, 2001,61 :4382-4385.
4Ohta M, Inoue H, Cottcelli MG, et al. The fhit gene spannig the chromosome 3p14.2 fragile site and renal carcinoma associated t (3;8) breakpoint is abnormal in digestive tract cancers [J]. Cell, 1996,81:587-597
5Pekarsky Y, Zanesi N, Palamarchuk A, et al. Fhit from gene discovery to cancer treament and prevention[J]. Lancet Oncol,2002,3:748-754
6Ozaki K, Enomoto T, Yosaino K, et al. Fhit alterations in endometrial carcinoma and hyperplasia[J] .Int J Cancer,2000,85:306-312
7Segawa T, SaSagawa T, Saijoh K, et al. Clinicopathological significance of fragile histidine triad transcription protein expression in endormetrial carcinoma[J] .Clin Cancer Res,2000,6:2341-2348
8Hendricks DT,Taylor R, Reed M, et al. Fhit gene expression in human ovarian, endometrial and cervical cancer cell lines [J]. Cancer Res, 1997 , 57 : 2112-2115
9Hadaczek P, Gronwald J, Chosia M, et al. Fhit protein expression in endometrial cancers no correlation with histologyical grade[J] .Pol J Pathol,2001,52:199-203
10Takai N, Miyazaki T, Nishida M, et al. Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma[J]. Cancer lett,2002,184:105-116
